New Assay for Patient Care and Use in Clinical Trials Could Lead to Expanded Treatment Options for Melanoma BURLINGTON, N.C.–(BUSINESS WIRE)–Finding treatment options for skin cancer may become easier with the launch of a new test by Labcorp (NYSE: LH), a leading global life sciences company. The new test measures Lymphocyte-activation gene 3 (LAG-3) expression … [Read more…]
Promising preclinical data for NGN-401 presented at 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) demonstrate significant survival benefit and reduced disease burden in Rett syndrome mouse model Results show Neurogene’s EXACT gene therapy regulates MECP2 gene expression to target levels, avoiding overexpression related toxicity EXACT platform holds potential to … [Read more…]
MENLO PARK, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in May and June. Details of the events are as follows: H.C. … [Read more…]
Study confirms the ability of ReCode’s Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform to deliver optimized, functional CFTR mRNA as an aerosol directly to specific cell targets Results show consistent rescue of CFTR function across multiple cystic fibrosis patient genotypes, including genotypes that do not respond to approved CFTR modulator treatments MENLO PARK, Calif. … [Read more…]
LCAP shareholders have approved the previously announced business combination at the Special Meeting held on May 18, 2022 Transaction Expected to Close May 20, 2022 CORAL GABLES, Fla.–(BUSINESS WIRE)–Lionheart Acquisition Corporation II (Nasdaq: LCAPU, LCAP, LCAPW, “Lionheart” or “LCAP”), a publicly traded special purpose acquisition company, today announced that shareholders of record as of April … [Read more…]
SAN FRANCISCO–(BUSINESS WIRE)–neuro42, Inc. (“neuro42” or the “Company”), a medical imaging, robotics, and AI technology company, today announced an exclusive licensing agreement with Johns Hopkins University (“Johns Hopkins”) for their MR compatible robot for head, neck and spine applications, with additional non-exclusive licenses for related technologies and patents. Developed by Dr. Dan Stoianovici, director of … [Read more…]
Chief Operating Officer Jessica Muse Assumes President Role for Company, Clinical Advisor Thomas Insel agrees to join Board SAN FRANCISCO–(BUSINESS WIRE)–#Cerebral–David Mou, MD MBA, the company’s President and Chief Medical Officer, has been named as Cerebral’s Chief Executive Officer. Cofounder Kyle Robertson leaves his position as CEO, effective immediately. “We thank Kyle for his service. … [Read more…]
WASHINGTON–(BUSINESS WIRE)–On May 16, Children’s Health Defense (CHD) and 50 other safe tech and health advocacy non-profits filed legal comments with the Federal Communications Commission (FCC) in response to the FCC’s request for comment on how to “prevent and eliminate digital discrimination.” The proceeding was required by the Infrastructure Investment and Jobs Act (“Infrastructure Act”) … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Antacids Global Market Report 2022, By Drug Class, Distribution Channel, Formulation Type” report has been added to ResearchAndMarkets.com’s offering. The global antacids market is expected to grow from $8.60 billion in 2021 to $9.13 billion in 2022 at a compound annual growth rate (CAGR) of 6.1%. The market is expected to reach $10.84 … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Global Osteoporosis Drugs Market, Size, Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis” report has been added to ResearchAndMarkets.com’s offering. This latest research report provides a detailed analysis of Osteoporosis Drugs Industry. The global osteoporosis drugs market is projected to reach $16.43 Billion in 2027, from $12.01 Billion in 2021. … [Read more…]
